Gastro-oesophageal reflux disease

被引:287
作者
Moayyedi, Paul
Talley, Nicholas J. [1 ]
机构
[1] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Motil Interest Grp, Rochester, MN 55905 USA
[2] McMaster Univ, Med Ctr, Dept Med, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada
关键词
D O I
10.1016/S0140-6736(06)68932-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gastro-oesophageal reflux disease refers to reflux of gastric contents into the oesophagus leading to oesophagitis, reflux: symptoms sufficient to impair quality of life, or long-term complications. Transient relaxation of the lower oesophageal sphincter is believed to be the primary mechanism of the disease although the underlying cause remains uncertain. Obesity and smoking are weakly associated with the disease and genetic factors might be important. A negative association with Helicobacter pylori exists, but eradication of H pylori does not seem to cause reflux disease. Diagnosis is imprecise as there is no gold standard. Reflux: symptoms are helpful in diagnosis but they lack sensitivity. Ambulatory oesophageal pH monitoring also seems to be insensitive despite high specificity Empirical acid suppression with a proton-pump inhibitor (PPI) has reasonable sensitivity but poor specificity. Some evidence suggests that once patients develop the disease, severity is determined early and patients seem to continue with that phenotype long term. Unfortunately, most patients do not respond to life-style advice and require further therapy. H. receptor antagonists and PPIs are better than placebo in oesophagitis, with a number needed to treat of five and two, respectively. In non-erosive reflux: disease, acid suppression is better than placebo but the response rate is lower. Most patients need long-term treatment because the disease usually relapses. The role of endoscopic therapy is uncertain. Anti-reflux surgery is probably as effective as PPI therapy although there is a low operative mortality and morbidity.
引用
收藏
页码:2086 / 2100
页数:15
相关论文
共 193 条
  • [51] Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease
    Fock, KM
    Talley, N
    Hunt, R
    Fass, R
    Nandurkar, S
    Lam, SK
    Goh, KL
    Sollano, J
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (04) : 357 - 367
  • [52] Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus
    Ford, AC
    Forman, D
    Reynolds, PD
    Cooper, BT
    Moayyedi, P
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2005, 162 (05) : 454 - 460
  • [53] FRAME MH, 1991, EUR J GASTROEN HEPAT, V3, P511
  • [54] GIBSON PG, 2003, COCHRANE DB SYST REV, V1
  • [55] RANITIDINE AND PLACEBO IN THE TREATMENT OF REFLUX ESOPHAGITIS - A DOUBLE-BLIND RANDOMIZED TRIAL
    GOY, JA
    MAYNARD, JH
    MCNAUGHTON, WM
    OSHEA, A
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1983, 2 (11) : 558 - 561
  • [56] GREEN JRB, 1995, BR J CLIN RES, V6, P63
  • [57] Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications
    Hampel, H
    Abraham, NS
    El-Serag, HB
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 143 (03) : 199 - 211
  • [58] Hansen JM, 1998, SCAND J GASTROENTERO, V33, P799
  • [59] Haque M, 2000, NEW ZEAL MED J, V113, P178
  • [60] Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux:: Bristol helicobacter project
    Harvey, RF
    Lane, JA
    Murray, LJ
    Harvey, IM
    Donovan, JL
    Nair, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7453): : 1417 - 1419